Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Haemopurification company expansion overseas

Aethlon Medical : 16 October, 2013  (Company News)
Aethlon Medical gains ground in the development and roll-out of haemopurification therapy worldwide
Haemopurification company expansion overseas


In recent months, Aethlon Medical launched and staffed a diagnostic subsidiary, expanded its intellectual property portfolio, and continued to generate revenues from established and newly awarded government contracts.  More importantly, says Chairman and CEO Jim Joyce, we achieved the most significant milestone in the history of our organization, FDA approval of an investigational device exemption (IDE) that allows us to initiate the first human Hemopurifier therapy studies in the United States.  As a result, we have an opportunity to reward our stakeholders though the established Wall Street model of demonstrating US clinical progression.  For those not familiar with our Hemopurifier, it is a first-in-class medical device that targets the rapid elimination of life-threatening infectious viruses and cancer glycopathogens from circulation.



As per the IDE approved protocol, we will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the protocol, which we previously conducted with success in India, will set the stage for pivotal studies required for market clearance in the USA.  The approval of our IDE has also unlocked the ability to advance clinical partnering programs with medical institutes that are pursuing indications of our Hemopurifier in cancer care.



In the coming weeks, we are scheduled to initiate Hemopurifier manufacturing to support our FDA approved study as well as our continued treatment endeavours overseas.  In this regard, I am pleased to share that our researchers along with collaborative assistance have discovered a processing technique that significantly optimizes the ability of the affinity agent immobilized within the Hemopurifier to bind viruses and other glycopathogen targets.  As you may recall, we previously reported that intermittent Hemopurifier administration during the first three days of interferon-based therapy resulted in undetectable viral load in as little as seven days in hard-to-treat HCV genotype-1 patients.  Based on a review of clinical literature, we believe such outcomes reflect a significant advancement in HCV care.  By incorporating our new processing techniques into our manufacturing protocol, we expect the optimized capture capabilities of the Hemopurifier will further augment the benefit of standard-of-care drug therapies.  We anticipate Hemopurifier manufacturing to be complete by year-end and then expect to begin treating patients in the first quarter of 2014.



Last month, we announced the launch of Exosome Sciences (ESI) as a subsidiary that is advancing exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions.  We also disclosed that we staffed ESI with two of the best-known thought leaders in the exosome industry.



Additionally, we referenced a plan to establish the ESI labs in a research facility located in Langhorne, Pennsylvania.  We reconsidered the Langhorne option and instead made the decision to execute a lease and are now building out ESI lab facilities at the Princeton Research Centre. This 260,000 square foot facility is ideally situated on the Princeton-Rutgers Route 1 Corridor ("Einstein Alley"), which provides easy access to both New York City and Philadelphia.  We are planning a small grand opening event for Aethlon shareholders in early November and will let you know once a date has been set.  Regardless, our goal is to transform ESI from a previously unvalued asset into a stand-alone organization that contributes measurable asset value on the balance sheet of Aethlon Medical.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo